ACR Acrux Ltd
- 0.074
- -0.002-2.63%
Acrux Ltd News
Percheron Therapeutics Appoints CFO
Percheron Therapeutics (ASX:PER) appointed Deborah Ambrosini as its chief financial officer and company secretary, effective immediately, according to a Monday filing with the Australian bourse. Ambro
Acrux, TruPharma Launch Dapsone 5% Gel in US
Pharmaceutical company Acrux (ASX:ACR) and its partner TruPharma introduced a generic version of the topical prescription medication Dapsone 5% Gel in the US, according to a Wednesday filing with the
Acrux Gets AU$3 Million Tax Rebate for Fiscal Year 2023
Acrux (ASX:ACR) received a rebate worth AU$2.9 million for the fiscal year ended June 30 as part of the Australian government's research and development tax incentive scheme. The scheme aims to encour
US FDA Approves Review of Acrux (ASX:ACR) Nitroglycerin Ointment
Acrux Limited (ASX:ACR) Insider Purchases A$91,665.00 in Stock
Acrux Limited (ASX:ACR – Get Rating) insider Donald Brumley bought 1,455,000 shares of the business's stock in a transaction dated Thursday, March 9th. The shares were purchased at an average cost of
Acrux Limited (ASX:ACR) Insider Buys A$91,665.00 in Stock
Acrux Limited (ASX:ACR – Get Rating) insider Donald Brumley acquired 1,455,000 shares of Acrux stock in a transaction that occurred on Thursday, March 9th. The stock was purchased at an average cost o
Acrux (ASX:ACR) Announces Buyout of Future Lenzetto Royalties
Acrux (ASX:ACR) Launches Prilocaine and Lidocaine Cream in US
BRIEF-Acrux Says Us FDA Accepted For Review Co's Abbreviated New Drug Application
Sept 13 (Reuters) - Acrux Ltd ACR.AX :* US FOOD AND DRUG ADMINISTRATION HAS ACCEPTED FOR REVIEW CO'S ABBREVIATED NEW DRUG APPLICATION FOR ITS GENERIC VERSION OF DAPSONE GEL, 5%Source text for Eikon:
Analysis
Price Target
No Data
